Approximately one‐half of individuals with cancer face personal economic burdens
associated with the disease and its treatment, a problem known as financial toxicity (FT). FT …

Abstract “Financial toxicity” has now become a familiar term used in the discussion of cancer
drugs, and it is gaining traction in the literature given the high price of newer classes of …

Abstract Background and Objectives The coronavirus disease 2019 (COVID-19) pandemic
has negatively affected persons with existing chronic health conditions. The pandemic also …

Objectives To explore the variation in understanding, attitudes and uptake of COVID-19
health advice during the 2020 pandemic lockdown by health literacy. Study design National …

Background: Patients with cancer experience financial toxicity from the costs of treatment, as
well as material and psychologic stress related to this burden. A synthesized understanding …

Despite the importance of chemotherapy-associated adverse events in oncology practice
and the broad range of interventions available to mitigate them, limited systematic efforts …

Financial toxicity is the adverse impact of a cancer diagnosis on a patient's financial well‐
being resulting from direct or indirect costs. Potential consequences of financial toxicity …

Financial toxicity describes the financial burden and distress that can arise for patients, and
their family members, as a result of cancer treatment. It includes direct out-of-pocket costs for …

Context No information is available on oncology patients' level of stress and symptom
burden during the coronavirus disease 2019 (COVID-19) pandemic. Objectives To evaluate …

Although there is no formal definition, financial toxicity (FT) refers to the detrimental effects of
the excess financial strain caused by the diagnosis of cancer on the well-being of patients …